Trial record 1 of 1 for: NCT05590403

Previous Study | Return to List | Next Study

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05590403

Recruitment Status : Active, not recruiting

First Posted : October 21, 2022

Last Update Posted : March 7, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

GlaxoSmithKline

Tracking Information

First Submitted Date ^ICMJE

October 18, 2022

First Posted Date ^ICMJE

October 21, 2022

Last Update Posted Date

March 7, 2024

Actual Study Start Date ^ICMJE

October 28, 2022

Actual Primary Completion Date

March 13, 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

RSV-A neutralization titers expressed as group geometric mean titer (GMT) ratio in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-A neutralization titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-B neutralization titers expressed as group GMT ratio in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-B neutralization titers expressed as group SRR difference in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-A neutralization titers expressed as group GMT ratio in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-A neutralization titers expressed as group SRR difference in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-B neutralization titers expressed as group GMT ratio in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-B neutralization titers expressed as group SRR difference in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]

Original Primary Outcome Measures ^ICMJE

RSV-A neutralization antibody titers expressed as group geometric mean titer (GMT) ratio in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-A neutralization antibody titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-B neutralization antibody titers expressed as group GMT ratio in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-B neutralization antibody titers expressed as group SRR difference in healthy participants compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-A neutralization antibody titers expressed as group GMT ratio in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-A neutralization antibody titers expressed as group SRR difference in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]
RSV-B neutralization antibody titers expressed as group GMT ratio in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) ]
RSV-B neutralization antibody titers expressed as group SRR difference in participants at increased risk of RSV-LRTD compared to OA [ Time Frame: 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1) ]

Change History

Current Secondary Outcome Measures ^ICMJE

Percentage of participants reporting each solicited administration site event (pain, redness and swelling) [ Time Frame: Within 4 days after study intervention administered on Day 1 ]
Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness) [ Time Frame: Within 4 days after study intervention administered at Day 1 ]
Percentage of participants reporting unsolicited adverse events (AEs) [ Time Frame: Within 30 days after study intervention administered at Day 1 ]
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Percentage of participants reporting any serious adverse events (SAEs) [ Time Frame: After study intervention administration (Day 1) up to Month 6 ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Percentage of participants reporting any potential immune mediated diseases (pIMDs) [ Time Frame: After study intervention administration (Day 1) up to Month 6 ]
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Percentage of participants reporting SAEs related to study intervention administration [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Percentage of participants reporting pIMDs related to study intervention administration [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Percentage of participants reporting any fatal SAEs [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
RSV-A neutralization titers expressed as GMT [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
RSV-B neutralization titers expressed as GMT [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Original Secondary Outcome Measures ^ICMJE

Percentage of participants reporting each solicited administration site event (pain, redness and swelling) [ Time Frame: Within 4 days after study intervention administered on Day 1 ]
Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness) [ Time Frame: Within 4 days after study intervention administered at Day 1 ]
Percentage of participants reporting unsolicited adverse events (AEs) [ Time Frame: Within 30 days after study intervention administered at Day 1 ]
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Percentage of participants reporting any serious adverse events (SAEs) [ Time Frame: After study intervention administration (Day 1) up to Month 6 ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Percentage of participants reporting any potential immune mediated diseases (pIMDs) [ Time Frame: After study intervention administration (Day 1) up to Month 6 ]
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Percentage of participants reporting SAEs related to study intervention administration [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Percentage of participants reporting pIMDs related to study intervention administration [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Percentage of participants reporting any fatal SAEs [ Time Frame: After study intervention administration (Day 1) up to study end (Month 12) ]
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
RSV-A neutralization antibody titers expressed as GMT [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
RSV-B neutralization antibody titers expressed as GMT [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers [ Time Frame: At pre-study intervention administration, 1 month, 6 months and at 12 months after study intervention administration ]
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Current Other Pre-specified Outcome Measures

Not Provided

Original Other Pre-specified Outcome Measures

Not Provided

Descriptive Information

Brief Title ^ICMJE

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Official Title ^ICMJE

A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults ≥60 Years of Age

Brief Summary

The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults ≥60 YOA

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase ^ICMJE

Phase 3

Study Design ^ICMJE

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Observer-blind for Cohort 1 (Day1-Day 31) and single-blind afterwards and open-label for Cohort 2

Primary Purpose: Prevention

Condition ^ICMJE

Respiratory Syncytial Virus Infections

Intervention ^ICMJE

Biological: RSVPreF3 OA investigational vaccine
One dose administered intramuscularly at Day 1.
Drug: Placebo
One dose administered intramuscularly at Day 1.

Study Arms ^ICMJE

Experimental: Adults HA-RSV Group
Healthy adults (HA) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.

Intervention: Biological: RSVPreF3 OA investigational vaccine
Placebo Comparator: Adults HA-Placebo Group
HA 50-59 YOA, who receive 1 dose of placebo at Day 1.

Intervention: Drug: Placebo
Experimental: Adults AIR-RSV Group
Adults at increased risk (AIR) 50-59 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.

Intervention: Biological: RSVPreF3 OA investigational vaccine
Placebo Comparator: Adults AIR-Placebo Group
Adults AIR 50-59 YOA, who receive 1 dose of placebo at Day 1.

Intervention: Drug: Placebo
Experimental: OA-RSV Group
Older adults (OA) ≥60 YOA, who receive 1 dose of RSVPreF3 OA investigational vaccine at Day 1.

Intervention: Biological: RSVPreF3 OA investigational vaccine

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Active, not recruiting

Actual Enrollment ^ICMJE

1576

Original Estimated Enrollment ^ICMJE

1520

Estimated Study Completion Date ^ICMJE

April 3, 2024

Actual Primary Completion Date

March 13, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol
Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure.

1. Specific inclusion criteria for all participants in Cohort 1 (Adults HA-RSV Group, Adults HA-Placebo Group, Adults AIR-RSV Group & Adults AIR-Placebo Group)
A male or female participant 50-59 YOA at the time of the study intervention administration.
Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy or post-menopause.
Female participants of childbearing potential may be enrolled in the study, if the participant:
- has practiced adequate contraception from 1 month prior to study intervention administration until study end for this study, and
- has a negative pregnancy test on the day of study intervention administration.

Specific inclusion criteria for participants in the Adults-HA Sub-cohort

Healthy participants as established by medical history and clinical examination before entering into the study.
Participants with chronic stable medical conditions with or without specific treatment, such as hypertension, hypercholesterolemia, or hypothyroidism, and who are not at increased risk for RSV-LRTD , are allowed to participate in this study if considered by the investigator as medically stable (no changes in the treatment or disease severity in the past 3 months).

Specific inclusion criteria for participants in the Adults-AIR Sub cohort

Participants should be diagnosed with at least 1 of the following medical conditions and have a stable condition (no changes in the treatment or disease severity in the past 3 months):

Chronic pulmonary disease resulting in activity restricting symptoms or use of long-term medication
Chronic cardiovascular disease
Diabetes mellitus: types 1 and 2
Other diseases at increased risk for RSV-LRTD disease
- Chronic kidney disease
- Chronic liver disease 2. Specific inclusion criteria for Cohort 2 (OA-RSV Group)
A male or female participant ≥60 YOA at the time of the study intervention administration.
Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease are allowed to participate in this study if considered by the investigator as medically stable (no changes in the treatment or disease severity in the past 3 months).
Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

Exclusion Criteria:

Medical conditions

Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination (no laboratory testing required).
History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention.
Hypersensitivity to latex.
Unstable chronic illness.
Any history of dementia or any medical condition that moderately or severely impairs cognition.
Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol. Study participants may decide to assign a caregiver to help them complete the study procedures.
Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or planned use during the study period (up to Visit 4, Month 12).
Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of study intervention administration, with the exception of inactivated and subunit influenza vaccines or COVID-19 vaccines (fully licensed or with EUA) which can be administered up to 14 days before or from 14 days after the study intervention administration.

Note: In case an emergency mass vaccination for an unforeseen public health threat is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.

Previous vaccination with an RSV vaccine, including investigational RSV vaccines.
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune modifying treatments or planned administration at any time up to the end of the study.
- Up to 3 months prior to the study intervention administration:
- For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
- Administration of immunoglobulins and/or any blood products or plasma derivatives.
- Up to 6 months prior to study intervention administration: long-acting immune modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).

Other exclusions Other exclusions for all participants

History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
Bedridden participants.
Planned move during the study period that will prohibit participating in the study until study end.
Participation of any study personnel or their immediate dependents, family, or household members.

Other exclusions for Cohort 1

Pregnant or lactating female.
Female planning to become pregnant or planning to discontinue contraceptive precautions.

Sex/Gender ^ICMJE

Sexes Eligible for Study:

All

Ages ^ICMJE

50 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers ^ICMJE

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Listed Location Countries ^ICMJE

Argentina, Canada, Germany, Japan, Netherlands, Poland, Spain, United States

Removed Location Countries

Administrative Information

NCT Number ^ICMJE

NCT05590403

Other Study ID Numbers ^ICMJE

219238
2022-001981-36 ( EudraCT Number )

Has Data Monitoring Committee

U.S. FDA-regulated Product

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Product Manufactured in and Exported from the U.S.:	No

IPD Sharing Statement ^ICMJE

Plan to Share IPD:	Yes
Plan Description:	IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials:	Study Protocol
Supporting Materials:	Statistical Analysis Plan (SAP)
Supporting Materials:	Informed Consent Form (ICF)
Supporting Materials:	Clinical Study Report (CSR)
Time Frame:	IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access Criteria:	Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.